The ongoing outbreak of coronavirus disease 2019 (COVID-19) started in December of 2019. It has surpassed the death toll of the SARS outbreak of 2003.
In 2018, a lot happened in global pharmaceuticals industry. For example, the approval of second CAR T-cell therapy tisagenlecleucel (Kymriah) signified the dramatic progress in the field. While the industry witnessed uncertainties due to the U.S. presidential elections and weak economic growth in 2017, steady growth has returned.
BCC Research’s just published report Opioid Drugs: Global Markets to 2023 provides a comprehensive overview of the opioid market as well as the market for abuse prevention technologies. This edited excerpt provides an overview of a few of these emerging technologies.
It is now normal to call biotech and small pharma the innovation engines for the pharmaceutical industry. IPO and ICOs abound, as dollars from venture capital truly flood the ecosystem. In 2018, biopharma investment is having a moment. Any big fluctuation, even a positive one, makes stakeholders nervous. Some of the investors might be tourists—Amazon, Google, Apple, IBM, JP Morgan, Berkshire Hathaway and a half dozen others are new entrants, whose long term goals remain unclear. Particularly disturbing are the health insurance and supply chain changes that make headlines, such as this one.